Antivascular endothelial growth factor receptor (anti-VEGFR) was used to normalize the tumor vascular system and restore its function and fostered further investigations, aiming at the formation of intratumoral immune cell phenotypes parallel to the normalization of blood vessels, as indicated by the reduction of tissue perfusion and intratumoral hypoxia [19, 20]. The gene discussed is KDR; the disease is neoplasm.